Sofirium Sorafenib Tablets IP 200 mg is a prescription oncology medicine identified as containing Sorafenib 200 mg per tablet.

Sorafenib is an oral multikinase inhibitor used as targeted anticancer therapy.

It inhibits several protein kinases involved in tumor-cell signaling and angiogenesis, the process through which tumors develop blood vessels.

Sorafenib is an established treatment option in selected settings involving hepatocellular carcinoma, advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid carcinoma.

The suitability of sorafenib depends on the cancer diagnosis, stage, previous treatment, patient condition and applicable regulatory approvals.

The stated 200 mg tablet strength does not represent a universal patient dose.

The product name includes IP (Indian Pharmacopoeia). Actual compliance with the relevant pharmacopoeial standard must be verified from approved manufacturer documentation.

The exact manufacturer, tablet composition, packaging and approved indications of Sofirium must be verified from its approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Sofirium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features